Topic: mergers and acquisitions
Shire's ability to market Cinryze for children as young as 6 with HAE. That could help Shire fend off an all-out attack from CSL.
Takeda's loss of market value is being cited by a group of 12 shareholders stepping up to oppose its acquisition of Shire.
J&J, Roche and Pfizer are most flexible in making M&A deals, but AstraZeneca might not be an easy target, a Leerink report shows.
Big Pink is going orange. That’s the brand color of its new parent U.S. pharma and healthcare agency, Precisioneffect.
Wacker Chemie, a chemical company based in Munich, purchased a Dutch biopharma manufacturing site from SynCo Bio Luxembourg for an undisclosed price.
Drug materials are targets of U.S.-China trade war, analysts see more hope in the Takeda-Shire deal, China puts forward policies that favors generics over brands.
Dendreon’s chairwoman said the infrastructure developed to produce and market Provenge has paved its way into CAR-T.
Takeda weighs a $52 billion Shire bid, WuXi gets approval for a $900M-plus Shanghai IPO, Aslan aims to raise $86 million through an IPO on Nasdaq.
Astellas buys Universal Cells, Teva is affected by Celltrion's manufacturing problem, Korea rolls out a digital health initiative.
J&J's diabetes unit attracts Chinese buyers, Novartis and Biocon form a biosimilar deal, plus Keytruda-Lenvima combo gets a breakthrough tag.